What is ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study?
CATEGORY:
ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study is a randomized, double Blind controlled trial comparing rituximab against cyclophosphamide in patients with connective tissue disease associated interstitial lung disease. NCT01862926
Save up to 80% off your prescriptions!
How do members experience ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study?
Top 5 reported purposes & perceived effectiveness
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Interstitial lung disease | 1 | 8 | |
| Mixed connective tissue disease | 1 | 8 | |
| Raynaud's disease | 1 | 8 |
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Fatigue | 1 | |
| Muscle pain | 1 | |
| Muscle tightness | 1 | |
| Nausea | 1 |
Side effect severity
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 1 | |
| Moderate | 4 | |
| Mild | 0 | |
| None | 3 |
Learn more about our community’s experience with ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
What are people saying about ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study?
6
6
members have reported taking ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
Join the conversation and connect with people who have taken ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study
Last updated: